SynthesisMedicine2026
A PRISMA-guided systematic review of pharmacogenetic anticancer clinical trials registered on clinicaltrials.gov.
Synthesis in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPharmacogenetics plays an increasingly important role in oncology by supporting individualized therapeutic strategies based on patient genetic profiles. ClinicalTrials.gov provides a valuable platform for evaluating global trends in pharmacogenetic anticancer clinical trials. This systematic review aimed to evaluate pharmacogenetic-focused anticancer clinical trials registered on ClinicalTrials.gov and summarize trends in study design, cancer types, targeted biomarkers, therapeutic interventions, and geographic distribution.
methodsA Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guided systematic review was conducted using ClinicalTrials.gov. Searches were performed between July 24 and July 26, 2025, using the terms "anticancer" AND "pharmacogenetics." Eligible studies included interventional and observational oncology trials containing a pharmacogenetic component. Data extracted included trial phase, study status, cancer type, pharmacogenetic targets, therapeutic interventions, sponsor type, and country of origin.
resultsA total of 12 trials met the inclusion criteria. Most studies were interventional (91.7%) and predominantly early-phase trials. Frequently investigated biomarkers included CYP450 enzymes, TPMT, UGT1A1, BRCA1/2, and Epidermal Growth Factor Receptor. Breast cancer, colorectal cancer, and non-small cell lung cancer were among the most commonly investigated malignancies. Most trials originated from the United States and Europe, while limited representation from low- and middle-income countries was observed. Increasing incorporation of multi-gene panels and biomarker-guided therapeutic strategies was identified.
conclusionPharmacogenetic approaches are increasingly being incorporated into anticancer clinical trials and may contribute to the advancement of precision oncology. However, broader global representation, larger late-phase trials, and more standardized biomarker integration remain necessary to support wider clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.